Crinetics Pharmaceuticals Inc
Geschlossen
BrancheGesundheitswesen
84.95 0.13
Übersicht
Veränderung der Aktienkurses
24h
Min
84.95
Max
84.95
Einkommen | 7M -121M |
|---|---|
Verkäufe | 14M 25M |
EPS | -1.14 |
Gewinnspanne | -481.149 |
Angestellte | 594 |
EBITDA | -4.7M -131M |
Empfehlungen | Neutral |
|---|---|
12-Monats-Prognose | +0.72% upside |
Marktkapitalisierung | 148M 9B |
|---|---|
Vorheriger Eröffnungskurs | 84.82 |
Vorheriger Schlusskurs | 84.95 |
Crinetics Pharmaceuticals Inc Chart
Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.
Ähnliche Nachrichten
Peer-Vergleich
Kursveränderung
Crinetics Pharmaceuticals Inc Prognose
Kursziel
By TipRanks
0.72% Vorteil
12-Monats-Prognose
Durchschnitt 85.56 USD 0.72%
Hoch 95 USD
Tief 80 USD
Basierend auf 11 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Crinetics Pharmaceuticals Inc – Dist angeboten haben.
Finanzen
$
Über Crinetics Pharmaceuticals Inc
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.